CO5140110A1 - Nuevos antibioticos macrolidos - Google Patents
Nuevos antibioticos macrolidosInfo
- Publication number
- CO5140110A1 CO5140110A1 CO99069359A CO99069359A CO5140110A1 CO 5140110 A1 CO5140110 A1 CO 5140110A1 CO 99069359 A CO99069359 A CO 99069359A CO 99069359 A CO99069359 A CO 99069359A CO 5140110 A1 CO5140110 A1 CO 5140110A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- optionally substituted
- hydrogen
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 41
- 125000001072 heteroaryl group Chemical group 0.000 abstract 27
- 229910052739 hydrogen Inorganic materials 0.000 abstract 19
- 239000001257 hydrogen Substances 0.000 abstract 19
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 14
- 125000003118 aryl group Chemical group 0.000 abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 11
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 125000000304 alkynyl group Chemical group 0.000 abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 5
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 102220092886 rs143733205 Human genes 0.000 abstract 3
- 102220084927 rs778740017 Human genes 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 102220315634 rs1196125127 Human genes 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 102220264985 rs182760732 Human genes 0.000 abstract 1
- 102220024746 rs199473444 Human genes 0.000 abstract 1
- 102200160920 rs35304565 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Un compuesto de fórmula<EMI FILE="99069359_1" ID="1" IMF=JPEG >O sus sales farmacéuticamente aceptables; en la que la línea de trazos entre las posiciones 10 y 11 representa un doble enlace opcional;A es 0 ó 1;R1 es hidrógeno o alquilo C1-C10, opcionalmente sustituido por fluoro, ciano, R7, R7O2C, R7C(O)NH y R7S(O)n, siendo n 0, 1 ó 2 y R7 alquilo C1-C6, alquenilo C2-C12, alquinilo C2-C12, (cicloalquil C3-C10)(alquilo C1-C6), (heterocicloalquil C2-C9)(alquilo C1-C6), (aril C6-C10)(alquilo C1-C6) o (heteroaril C2-C9)(alquilo C1-C6), estando los grupos alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo opcionalmente sustituidos por uno a tres halógenos, alcoxi C1-C3, hidroxi, nitro, ciano, arilo C6-C10, heteroarilo C2-C9, R8R9N, R8C(0), R8C(0)0, R80C(0), R8C(0)NH, R8NHC(0), R8R9NC(0) y R80C(0)2, siendo cada uno de R8 y R9 independientemente hidrógeno o alquilo C1-C6 opcionalmente sustituido por arilo C6-C10 o heteroarilo C2-C9; R2 es hidrógeno o un grupo protector de hidroxi; R3 es amino, ciano, N3, R10NH, R10C(O)NH, R10NHC(O)NH, R10NHC(S)NH, R10NHNHC(O)NH, R10ONHC(O)NH, R10O, R10OC(O)NH, R10S(O)n, R10fosforamido, R10sulfonamido, SH, R10S, siendo n como se ha definido antes y R10 alquilo C1-C6, alquenilo C2-C12, alquinilo C2-C12, (cicloalquil C3-C10)(alquilo C1-C6), (heterocicloalquil C2-C9)(alquilo C1-C6), arilo C6-C10, (aril C6-C10)(alquilo C1-C6) o (heteroaril C2-C9)(alquilo C1-C6); estando los grupos alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo opcionalmente sustituidos por uno a tres sustituyentes seleccionados independientemente de halógeno, alcoxi C1-C3, hidroxi, nitro, ciano, arilo C6-C10, heteroarilo C2-C9, R8R9N, R8C(0), R8C(0)0, R8OC(0), R8C(0)NH, R8NHC(0), R8R9NC(O) y R80C(O)2, siendo cada uno de R8 y R9 independientemente hidrógeno o alquilo C1-C6, opcionalmente sustituido por arilo C6-C10 o heteroarilo C2-C9; o R3 es R12R13N, siendo cada uno de R12 y R13 independientemente hidrógeno, alquilo C1-C6, (aril C6-C10)(alquilo C1-C6) o (heteroaril C2-C9)(alquilo C1-C6); R4 es hidrógeno, metilo opcionalmente sustituido por uno a dos nitro, ciano, R14C(O) y R140C(0); o R4 es N3, R14O, R14NH, R14S, siendo R14 alquilo C1-C6, alquenilo C2-C12, - 2 - alquinilo C2-C12, (cicloalquil C3-C10)(alquilo C1-C6), (heterocicloalquil C2-C9)(alquilo C1-C6), arilo C6-C10, (aril C6-C10)(alquilo C1-C6) o (heteroaril C2-C9)(alquilo C1-C6); estando los grupos alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo opcionalmente sustituidos por uno a tres sustituyentes seleccionados independientemente de halógeno, alcoxi C1-C3, hidroxi, nitro, ciano, arilo C6-C10, heteroarilo C2-C9, R8R9N, R8C(O), R8C(O)O, R8OC(O), R8C(O)NH, R8NHC(O), R8R9NC(O) y R8OC(O)2, siendo cada uno de R8 y R9 independientemente hidrógeno o alquilo C1-C6, opcionalmente sustituido por arilo C6-C10 o heteroarilo C2-C9; o R4 es R15N(alquilo C1-C6), siendo R15 hidrógeno, alquilo C1-C6, (aril C6-C10)(alquilo C1-C6) o (heteroaril C2-C9)(alquilo C1-C6);X es oxígeno o NOR16, donde R16 es alquilo C1-C6, alquenilo C2-C12, alquinilo C2-C12, (cicloalquil C3- C10)(alquilo C1-C6), (heterocicloalquil C2-C9)(alquilo C1-C6), (aril C6-C10)(alquilo C1-C6) o (heteroaril C2-C9)(alquilo C1-C6); estando los grupos alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo opcionalmente sustituidos por uno a tres sustituyentes seleccionados independientemente de halógeno, alcoxi C1-C3, hidroxi, nitro, ciano, arilo C6-C10, heteroarilo C2-C9, R8R9N, R8C(O), R8C(O)O, R8OC(O), R8C(O)NH, R8NHC(O), R8R9NC(O) y R8OC(O)2, siendo cada uno de R8 y R9 independientemente hidrógeno o alquilo C1-C6, opcionalmente sustituido por arilo C6-C10 o heteroarilo C2-C9; R5 es hidrógeno o metilo; o R3 y R4 pueden tomarse junto con los átomos de carbono a los que están unidos formando<EMI FILE="99069359_2" ID="2" IMF=JPEG >en la que la línea de trazos, entre el nitrógeno y la variable W de la fórmula II, representa un doble enlace opcional; W es C=O, C=S, SO2 o C=NR10, siendo R10 como se ha definido antes; Y es oxígeno, azufre o NR17, donde R17 es hidrógeno, R19, R19O o R19NH, siendo R19 hidrógeno, alquilo C1-C6, alquenilo C2-C12, alquinilo C2-C12, (cicloalquil C3-C10)(alquilo C1-C6), (heterocicloalquil C2-C9)(alquilo C1-C6), arilo C6-C10, (aril C6-C10)(alquilo C1-C6) o (heteroaril C2-C9)(alquilo C1-C6); estando los grupos alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo opcionalmente sustituidos por uno a tres sustituyentes seleccionados independientemente de halógeno, alcoxi C1-C3, hidroxi, nitro, ciano, arilo C6-C10, heteroarilo C2-C9, R8R9N, R8C(O), R8C(O)O, R8OC(O), R8C(O)NH, R8NHC(O), R8R9NC(O) y R8OC(O)2, siendo cada uno de R8 y R9 independientemente hidrógeno o alquilo C1-C6, opcionalmente sustituido por arilo C5-C10 o heteroarilo C2-C9;R18 es hidrógeno, alquilo C1-C6, arilo C6-C10, (aril C6- C10)(alquilo C1-C6) o (heteroaril C2-C9)(alquilo C1-C6); estando los grupos arilo y heteroarilo opcionalmente sustituidos por uno a tres sustituyentes seleccionados independientemente de halógeno, alcoxi C1-C3, hidroxi, nitro, ciano, arilo C6-C10, heteroarilo C2-C9, R20R21N, R20C(O), R20C(O)O, R20OC(O), R20C(O)NH, R20NHC(0), R20R21NC(O) y R20OCO2, siendo cada uno de R20 y R21 independientemente hidrógeno, alquilo C1-C6, opcionalmente sustituido por acilo C6-C10 o arilo C5-C10 o heteroarilo C2-C9;R6 es hidrógeno, alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, (alcoxi C1-C6)(alquilo C1-C6) o (alquiltio C1-C6)(alquilo C1-C6), estando los grupos alquilo, alquenilo, alquinilo o alcoxi opcionalmente sustituidos por uno a tres sustituyentes seleccionados independientemente de hidroxi y halógeno; o R6 es cicloalquilo C3-C10 o cicloalquenilo C5-C10, opcionalmente sustituido por alquilo C1-C6 o halógeno;o R6 es heterocicloalquilo C2-C8 o heteroarilo C2-C9, opcionalmente sustituido por alquilo C1-C6, alquenilo C2-C8, alquinilo C2-C8, cicloalquilo C3-C10 cicloalquenilo C5-C10 o arilo, estando el grupo arilo opcionalmente sustituido por alquilo, alcoxi C1-C6 o halógeno; con la condición de que al menos uno de R17 o R18 es hidrógeno; con la condición de que cuando la línea de trazos entre las posiciones 10 y 11 representa un doble enlace, R4 es hidrógeno; y con la condición de que cuando a es cero; R1 es hidrógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10683698P | 1998-11-03 | 1998-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5140110A1 true CO5140110A1 (es) | 2002-03-22 |
Family
ID=22313524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99069359A CO5140110A1 (es) | 1998-11-03 | 1999-11-03 | Nuevos antibioticos macrolidos |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20020040007A1 (es) |
| EP (1) | EP1124837A2 (es) |
| JP (1) | JP4043191B2 (es) |
| KR (1) | KR20010083944A (es) |
| CN (1) | CN1376160A (es) |
| AP (1) | AP2001002131A0 (es) |
| AU (1) | AU5995299A (es) |
| BG (1) | BG105543A (es) |
| BR (1) | BR9914998A (es) |
| CA (1) | CA2349338C (es) |
| CO (1) | CO5140110A1 (es) |
| CZ (1) | CZ20011512A3 (es) |
| EA (1) | EA200100396A1 (es) |
| EE (1) | EE200100245A (es) |
| GT (1) | GT199900192A (es) |
| HK (1) | HK1049010A1 (es) |
| HR (1) | HRP20010306A2 (es) |
| HU (1) | HUP0104192A3 (es) |
| ID (1) | ID28286A (es) |
| IL (1) | IL142628A0 (es) |
| IS (1) | IS5919A (es) |
| MA (1) | MA26703A1 (es) |
| NO (1) | NO20012155L (es) |
| OA (1) | OA11670A (es) |
| PA (1) | PA8485101A1 (es) |
| PE (1) | PE20001289A1 (es) |
| PL (1) | PL348114A1 (es) |
| SK (1) | SK5812001A3 (es) |
| SV (1) | SV1999000188A (es) |
| TN (1) | TNSN99205A1 (es) |
| TR (4) | TR200101241T2 (es) |
| UY (1) | UY25780A1 (es) |
| WO (1) | WO2000026224A2 (es) |
| ZA (1) | ZA200103289B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP9801420A0 (en) * | 1998-01-02 | 1998-12-31 | Pfizer Prod Inc | Novel macrolides. |
| CA2349338C (en) | 1998-11-03 | 2005-12-06 | Pfizer Products Inc. | Novel macrolide antibiotics |
| BR9916969A (pt) | 1999-01-27 | 2001-11-06 | Pfizer Prod Inc | Antibióticos cetólidos |
| AU4354900A (en) | 1999-04-16 | 2000-11-02 | Kosan Biosciences, Inc. | Ketolide antibacterials |
| US6590083B1 (en) | 1999-04-16 | 2003-07-08 | Ortho-Mcneil Pharmaceutical, Inc. | Ketolide antibacterials |
| US6451768B1 (en) | 1999-04-16 | 2002-09-17 | Kosan Biosciences, Inc. | Macrolide antiinfective agents |
| US6939861B2 (en) | 1999-04-16 | 2005-09-06 | Kosan Biosciences, Inc. | Amido macrolides |
| ES2272273T3 (es) | 1999-04-16 | 2007-05-01 | Kosan Biosciences, Inc. | Agentes antiinfecciosos macrolidos. |
| US6514944B2 (en) | 1999-04-16 | 2003-02-04 | Kosan Biosciences, Inc. | Macrolide antiinfective agents |
| WO2000071557A1 (en) | 1999-05-24 | 2000-11-30 | Pfizer Products Inc. | 13-methyl-erythromycin derivatives |
| EP1114826A3 (en) * | 1999-12-29 | 2001-10-31 | Pfizer Products Inc. | Novel antibacterial and prokinetic macrolides |
| EP1146051A3 (en) * | 2000-04-10 | 2001-10-31 | Pfizer Products Inc. | Erythromycin A derivatives |
| DK1167376T3 (da) | 2000-06-30 | 2004-10-25 | Pfizer Prod Inc | Makrolidantibiotika |
| JP2008508322A (ja) * | 2004-07-28 | 2008-03-21 | ランバクシー ラボラトリーズ リミテッド | 抗菌剤としてのケトライド誘導体 |
| WO2006046112A2 (en) * | 2004-10-25 | 2006-05-04 | Ranbaxy Laboratories Limited | Ketolide derivatives as antibacterial agents |
| EP1836211B1 (en) * | 2004-12-21 | 2010-03-03 | Pfizer Products Inc. | Macrolides |
| US20090130225A1 (en) * | 2005-11-23 | 2009-05-21 | Anjan Chakrabarti | Macrolides derivatives as antibacterial agents |
| EP1957508A2 (en) * | 2005-11-23 | 2008-08-20 | Ranbaxy Laboratories Limited | Ketolide derivatives as antibacterial agents |
| US7801502B2 (en) * | 2006-12-18 | 2010-09-21 | Aai Corporation | Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems |
| US8409628B2 (en) | 2010-02-04 | 2013-04-02 | Penguin IP Holdings, Inc. | Methods and compositions for oxygenation of skin to treat skin disorders |
| US8900601B2 (en) | 2010-03-31 | 2014-12-02 | Jennifer Bartels | Permeable mixtures, methods and compositions for the skin |
| CN105358141A (zh) * | 2013-05-01 | 2016-02-24 | 尼奥酷里私人有限公司 | 治疗细菌感染的方法 |
| RU2537143C1 (ru) * | 2013-11-08 | 2014-12-27 | Государственное научное учреждение Ставропольский научно-исследовательский институт животноводства и кормопроизводства РАСХН | Препарат для лечения и профилактики мастита у коров |
| WO2018080072A2 (ko) * | 2016-10-27 | 2018-05-03 | 한국생명공학연구원 | 신규한 매크로라이드계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 말라리아의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU43006B (en) * | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| IL99995A (en) * | 1990-11-21 | 1997-11-20 | Roussel Uclaf | Erythromycin derivatives, their preparation and pharmaceutical compositions containing them |
| FR2697524B1 (fr) | 1992-11-05 | 1994-12-23 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| US5527780A (en) | 1992-11-05 | 1996-06-18 | Roussel Uclaf | Erythromycin derivatives |
| US5332807A (en) | 1993-04-14 | 1994-07-26 | Merck & Co., Inc. | Process of producing 8A- and 9A-azalide antibiotics |
| FR2702480B1 (fr) * | 1993-03-09 | 1995-04-28 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| HRP931480B1 (en) | 1993-12-08 | 1997-08-31 | Sour Pliva | 9a-N-(N'-CARBAMONYL) and 9a-N-(N'-THIOCARBAMONYL) DERIVATES OF 9-DEOXO-9a-HOMOERYTHROMYCIN A |
| HRP950145A2 (en) | 1995-03-27 | 1997-08-31 | Sour Pliva | New compounds of the secomacrolide and secoazalide class and a process for the preparation thereof |
| HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| AU2340797A (en) | 1996-05-07 | 1997-11-26 | Abbott Laboratories | 6-o-substituted erythromycins and method for making them |
| CA2259463A1 (en) | 1996-07-05 | 1998-01-15 | Biotica Technology Limited | Polyketides and their synthesis |
| ATE296832T1 (de) | 1996-09-04 | 2005-06-15 | Abbott Lab | 6-o-substituierte ketoliden mit antibakteriellen wirkung |
| UA51730C2 (uk) | 1996-09-04 | 2002-12-16 | Ебботт Лабораторіз | 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців |
| HRP960497B1 (en) | 1996-10-28 | 2003-08-31 | Pliva Pharm & Chem Works | 9-n-ethenyl derivatives of 9(s)-erythromycylamine |
| HN1998000074A (es) | 1997-06-11 | 1999-01-08 | Pfizer Prod Inc | Derivados de macrolidos c-4 sustituidos |
| US6407074B1 (en) | 1997-06-11 | 2002-06-18 | Pfizer Inc | C-4″-substituted macrolide derivatives |
| EP0895999A1 (en) | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
| US6339063B1 (en) | 1997-09-10 | 2002-01-15 | Merck & Co., Inc. | 9a-azalides as veterinary antimicrobial agents |
| EE04681B1 (et) | 1997-10-16 | 2006-08-15 | PLIVA, farmaceutska industrija, dionicko dru�tvo | 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon |
| DE69919769T2 (de) | 1998-03-03 | 2005-01-27 | Pfizer Products Inc., Groton | 3,6-Ketal-Makrolidantibiotika |
| CA2349338C (en) | 1998-11-03 | 2005-12-06 | Pfizer Products Inc. | Novel macrolide antibiotics |
| WO2000071557A1 (en) | 1999-05-24 | 2000-11-30 | Pfizer Products Inc. | 13-methyl-erythromycin derivatives |
| EP1114826A3 (en) | 1999-12-29 | 2001-10-31 | Pfizer Products Inc. | Novel antibacterial and prokinetic macrolides |
| EP1122261A3 (en) | 2000-01-31 | 2001-09-26 | Pfizer Products Inc. | 13 and 14-membered antibacterial macrolides |
| DK1167376T3 (da) | 2000-06-30 | 2004-10-25 | Pfizer Prod Inc | Makrolidantibiotika |
| WO2003004509A2 (en) | 2001-07-03 | 2003-01-16 | Chiron Corporation | C12 modified erythromycin macrolides and ketolides having antibacterial activity |
-
1999
- 1999-10-18 CA CA002349338A patent/CA2349338C/en not_active Expired - Fee Related
- 1999-10-18 ID IDW20010956D patent/ID28286A/id unknown
- 1999-10-18 SK SK581-2001A patent/SK5812001A3/sk unknown
- 1999-10-18 CN CN99812941A patent/CN1376160A/zh active Pending
- 1999-10-18 WO PCT/IB1999/001701 patent/WO2000026224A2/en not_active Application Discontinuation
- 1999-10-18 OA OA1200100102A patent/OA11670A/en unknown
- 1999-10-18 CZ CZ20011512A patent/CZ20011512A3/cs unknown
- 1999-10-18 AP APAP/P/2001/002131A patent/AP2001002131A0/en unknown
- 1999-10-18 PL PL99348114A patent/PL348114A1/xx not_active Application Discontinuation
- 1999-10-18 TR TR2001/01241T patent/TR200101241T2/xx unknown
- 1999-10-18 KR KR1020017005535A patent/KR20010083944A/ko not_active Application Discontinuation
- 1999-10-18 TR TR2002/00435T patent/TR200200435T2/xx unknown
- 1999-10-18 EA EA200100396A patent/EA200100396A1/ru unknown
- 1999-10-18 TR TR2002/00436T patent/TR200200436T2/xx unknown
- 1999-10-18 TR TR2002/00434T patent/TR200200434T2/xx unknown
- 1999-10-18 AU AU59952/99A patent/AU5995299A/en not_active Abandoned
- 1999-10-18 HU HU0104192A patent/HUP0104192A3/hu unknown
- 1999-10-18 JP JP2000579612A patent/JP4043191B2/ja not_active Expired - Fee Related
- 1999-10-18 BR BR9914998-2A patent/BR9914998A/pt not_active IP Right Cessation
- 1999-10-18 EP EP99971424A patent/EP1124837A2/en not_active Withdrawn
- 1999-10-18 IL IL14262899A patent/IL142628A0/xx unknown
- 1999-10-18 EE EEP200100245A patent/EE200100245A/xx unknown
- 1999-10-29 UY UY25780A patent/UY25780A1/es unknown
- 1999-10-29 PE PE1999001084A patent/PE20001289A1/es not_active Application Discontinuation
- 1999-10-29 SV SV1999000188A patent/SV1999000188A/es not_active Application Discontinuation
- 1999-11-02 PA PA19998485101A patent/PA8485101A1/es unknown
- 1999-11-02 TN TNTNSN99205A patent/TNSN99205A1/fr unknown
- 1999-11-02 MA MA25832A patent/MA26703A1/fr unknown
- 1999-11-03 CO CO99069359A patent/CO5140110A1/es unknown
- 1999-11-03 GT GT199900192A patent/GT199900192A/es unknown
-
2001
- 2001-04-17 IS IS5919A patent/IS5919A/is unknown
- 2001-04-23 ZA ZA200103289A patent/ZA200103289B/xx unknown
- 2001-04-30 HR HR20010306A patent/HRP20010306A2/hr not_active Application Discontinuation
- 2001-05-02 NO NO20012155A patent/NO20012155L/no not_active Application Discontinuation
- 2001-05-29 BG BG105543A patent/BG105543A/xx unknown
- 2001-10-01 US US09/969,486 patent/US20020040007A1/en not_active Abandoned
-
2002
- 2002-07-24 US US10/206,652 patent/US6835716B2/en not_active Expired - Fee Related
-
2003
- 2003-02-18 HK HK03101144.0A patent/HK1049010A1/zh unknown
-
2004
- 2004-07-21 US US10/896,293 patent/US7071170B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5140110A1 (es) | Nuevos antibioticos macrolidos | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| ES2258459T3 (es) | Pirrolotriazinas inhibidoras de quinasas. | |
| RS52562B (en) | (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I | |
| ATE282614T1 (de) | Phenylharnstoff und phenylthioharnstoffderivate | |
| ES2183548T3 (es) | Dihidropirimidinas. | |
| CO5540391A2 (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibi dores de la fosfodiesterasa | |
| AR083167A1 (es) | Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas | |
| MX9205309A (es) | Nuevos taxanos substituidos con furilo y tienilo y composiciones farmaceuticas que los contienen | |
| CO5580746A2 (es) | Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina | |
| CO5251440A1 (es) | Derivados de heterociclil-fenil-oxazolidin-tiofencarboxamida, su procedimiento de obtencion y medicamentos que los contienen | |
| CO4900062A1 (es) | Piridinas condensadas con heterociclos | |
| CY1108313T1 (el) | Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6 | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| ECSP088805A (es) | 2-(piridin-2-il)-pirimidinas como fungicidas | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| CO5631434A2 (es) | Derivados de piridina-carboxamida y su uso como plaguicidas | |
| CO4990960A1 (es) | Derivados de cetolidos 2-halo-6-o sustituidos | |
| CO4990972A1 (es) | Derivados de eritromicina en puente 6,11 | |
| CY1106692T1 (el) | Παραγωγα του αλοξενοϋλ-κυκλοπροπαν-1-καρβοξυλικου οξεος | |
| ES2142773B1 (es) | Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida. | |
| BR0317970A (pt) | Derivados de benzoìla substituìdos como herbicidas | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| PE14696A1 (es) | Derivado de fenetanolamina |